Incyte Corporation (INCY)

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (INCY 2.23%) stock over the past few days. The gloom this produced was pushing the biotech's share...

Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor expectations.

Statistical significance achieved with both doses of povorcitinib in both phase 3 STOP-HS studies treating patients with Hidradenitis suppurativa. The global Hidradenitis Suppurativa market size is ex...

Shares of Incyte (INCY) sank nearly 10% Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.

The biopharmaceutical company announces positive results from two skin disease treatment studies. But Wall Street doesn't think it was enough.

Incyte Corp  (NASDAQ:INCY) stock is down 11.4% to trade at $60.16 at last glance, after the pharmaceutical company's phase three trial data for its skin disease treatment showed it was only effective ...

On Monday, Incyte Corporation INCY released topline results from its pivotal Phase 3 STOP-HS clinical trial program of povorcitinib, an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years...

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday.

Incyte said on Monday its experimental drug has met the main goal in two separate late-stage studies testing it in patients with an inflammatory skin condition called hidradenitis suppurativa.